Repligen | RGEN - Gross Profit On Sales


Repligen reported $103.83M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Agilent USD 946M 44M Dec/2025
Align Technology USD 683.59M 44.39M Dec/2025
Bio Techne USD 191.28M 3.16M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Bruker USD 449.2M 69.8M Dec/2025
Charles River Laboratories USD 271.96M 39.43M Dec/2025
Danaher USD 3.97B 443M Dec/2025
Dentsply International USD 443M 2M Dec/2025
Exact Sciences USD 583.93M 21.48M Sep/2025
General Electric Aerospace USD 3.8B 118M Dec/2025
Henry Schein USD 1.06B 37M Dec/2025
Illumina USD 759M 26M Dec/2025
IQVIA Holdings USD 1.12B 32M Dec/2025
Mettler Toledo International USD 675.44M 65.98M Dec/2025
Myriad Genetics USD 146.8M 3M Dec/2025
OraSure Technologies USD 11.34M 435K Dec/2025
Pacific Biosciences Of California USD 15.74M 601K Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Repligen USD 103.83M 3.32M Dec/2025
Revvity USD 421.66M 47.06M Dec/2025
Standard Biotools USD 11.38M 1.9M Dec/2025
Thermo Fisher Scientific USD 4.64B 419M Dec/2025
Waters USD 557.42M 97.44M Dec/2025
West Pharmaceutical Services USD 303.9M 9.6M Dec/2025